Explore a question

Bone health and osteopenia in midlife: what the evidence says about what helps

Bone loss doesn't cause symptoms you can feel, so many women first hear about it from a bone density scan — sometimes with a word like "osteopenia" they weren't expecting. That can be worrying, and it's hard to find a clear answer on what actually helps. This page gathers what M-1 holds on how bone changes around menopause, who is advised to be checked, and the options that have been studied: medicines, exercise, and supplements.

What research suggests

Bone loss around menopause

Bone loss speeds up around menopause. In SWAN, a US study that followed 862 women through the transition, bone density loss began about a year before the final period and was fastest from then until two years after it, then slowed but didn't stop. Over 10 years women lost about 10% of their spine bone density and 9% at the hip, most of it in those three years. On average, loss was slower in women with a higher BMI and in African American women, and faster in Chinese and Japanese women.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

What osteopenia means

Osteopenia means bone density below the young-adult average but not low enough to count as osteoporosis (a T-score between -1.0 and -2.5). It's a sign of higher fracture risk rather than a disease in itself — and because it's so common, most fractures in postmenopausal women happen in women with osteopenia, not osteoporosis. Guidelines base decisions on overall fracture risk, which also depends on age, previous fractures, smoking, low body weight, and other health conditions and medicines, not on the T-score alone.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

Who is advised to have a bone density scan

The US Preventive Services Task Force recommends screening for osteoporosis in all women 65 and older, and in postmenopausal women under 65 whose fracture risk is raised, judged by a clinical risk assessment. The Menopause Society lists older age, genetics, smoking, thinness, and many diseases and medicines that affect bone among the main risk factors, and advises good nutrition (especially protein, calcium, and vitamin D), regular physical activity, and avoiding smoking and excess alcohol for all postmenopausal women.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

What remains uncertain

A bone density result is only one part of fracture risk — age, previous fractures, falls, smoking, body weight, family history, other health conditions, and medicines matter too. Research reports averages, so it can't tell you your own risk or which option suits you; that's a conversation to have with a clinician who knows your history.

What people try, and what the evidence says

Grouped by type, not ranked. An evidence grade describes the research — it doesn't tell you whether an option is suitable, safe, or right for you.

Options to discuss with a clinician

Bone medicines for osteoporosis

For postmenopausal women with osteoporosis, the American College of Physicians' 2023 guideline strongly recommends a bisphosphonate as the first medicine to lower fracture risk (based on high-certainty evidence). It suggests denosumab as a second option for women who can't take or don't tolerate bisphosphonates, and romosozumab or teriparatide, followed by a bisphosphonate, only for women at very high fracture risk. The Menopause Society also lists estrogen agonists/antagonists among approved options. Which medicine, if any, suits you depends on your fracture risk and health history.

AStrong evidence

Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.

Bone medicine for osteopenia

Trials show a bone medicine can also prevent fractures in women with osteopenia. In a 6-year trial of 2,000 women aged 65 and over with osteopenia, an infusion of the bisphosphonate zoledronate every 18 months lowered the risk of fragility fractures by about a third compared with placebo — about 15 women treated to prevent one fracture. In a 10-year trial of 1,054 women aged 50 to 60 with bone density below the young-adult average but not in the osteoporosis range, two zoledronate infusions five years apart reduced spine fractures seen on X-ray (6.3% vs 11.1%). The American College of Physicians' 2023 guideline suggests an individual decision about bisphosphonates for women over 65 with osteopenia.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

Hormone therapy and bone

In the Women's Health Initiative trial of 16,608 postmenopausal women aged 50 to 79, estrogen plus progestin reduced fractures compared with placebo (8.6% vs 11.1% of women over about 5.6 years) and increased hip bone density. But when the trial weighed all health outcomes together, it found no overall net benefit, even in women at high fracture risk. The Menopause Society's 2021 position statement lists estrogen among the therapies available to prevent bone loss in women at high risk, especially perimenopausal women with low bone density and other risk factors.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

Movement and nutrition

Balance and bone

Resistance training combined with tailored impact and balance work supports bone mineral density and lowers fall risk. The right dose depends strongly on individual fracture and fall risk, so this should be individualized rather than applied as one-size-fits-all.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

Calcium from food

Menopause increases bone-loss risk; clinical reviews identify about 1,200mg/day total calcium, preferably from food, as the target for most postmenopausal women, with vitamin D supporting calcium absorption.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

Strength and impact training for low bone mass

Supervised high-intensity strength and impact training improved bone density in women who already had low bone mass. In the LIFTMOR trial, 101 postmenopausal women with osteopenia or osteoporosis did 8 months of twice-weekly, 30-minute supervised sessions of heavy lifting and impact work. Their spine bone density rose about 2.9% while that of a low-intensity home-exercise group fell about 1.2%, they did better on every strength and balance test, and there was one minor side effect (a back spasm). Participants were screened first and closely supervised, so these results apply to that kind of program.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

See the routines and recipes in Studio →

Supplements

Vitamin D and calcium

Whether vitamin D and calcium supplements help prevent fractures depends on who takes them. The US Preventive Services Task Force recommends against daily low-dose supplements (400 IU or less of vitamin D and 1,000 mg or less of calcium) to prevent fractures in postmenopausal women living in the community, and found too little evidence to judge higher doses. That advice doesn't apply to women with osteoporosis, a previous fracture, a high risk of falls, or vitamin D deficiency.

BModerate evidence

There is reasonably consistent research, but important limitations or unanswered questions remain.

Algal (algae-derived) calcium

Algae-derived calcium hasn't been shown to protect bones better than other forms of calcium. The studies behind marketing claims for one brand were observational or open-label, with no placebo group: women's bone scans were compared with the bone loss researchers expected, and one study was partly funded by a company in which its lead author held shares. The products tested also contained vitamin D, vitamin K2, and other minerals — one version included strontium, which makes bone density scans read higher than the bone's calcium alone would — so the results can't show that the algae source itself made a difference.

DVery limited evidence

Insufficient or very uncertain research for a health-effect claim. It's included because people ask about it, not because it's established care.

What does this grade mean?

Save and prepare

Questions you save go to Your Record and can be added to your next Doctor Prep.

Should I have a bone density scan, and if so, when?
My scan showed osteopenia — what is my overall fracture risk, and does it change what I should do?
Would a bone medicine make sense for me, and what are the benefits and downsides?
Could hormone therapy help protect my bones, given my health history?
Is the exercise I do enough for my bones, and is heavier strength or impact training safe for me?
Am I getting enough calcium and vitamin D, and do I need a supplement?
Could any of my medicines or health conditions be affecting my bones?

Want to keep track over time? Record what you've noticed in Today

M-1 is looking into

Vitamin K2 for bone health